

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7195716

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
TAKEDA PHARMACEUTICAL COMPANY LIMITED	11/09/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	RESOLVE THERAPEUTICS, LLC
<b>Street Address:</b>	721 1ST AVE. N.
<b>City:</b>	ST. PETERSBURG
<b>State/Country:</b>	FLORIDA
<b>Postal Code:</b>	33701
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17560522
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6179372300
<b>Email:</b>	jvecchia@cooley.com
<b>Correspondent Name:</b>	COOLEY LLP, ATTN: PATENT GROUP
<b>Address Line 1:</b>	1299 PENNSYLVANIA AVENUE, NW
<b>Address Line 2:</b>	SUITE 700
<b>Address Line 4:</b>	WASHINGTON, D.C. 20004
<b>ATTORNEY DOCKET NUMBER:</b>	RSLV-013C01US 344300-2327
<b>NAME OF SUBMITTER:</b>	ERIKA L. WALLACE
<b>SIGNATURE:</b>	/ Erika L. Wallace /
<b>DATE SIGNED:</b>	02/25/2022
<b>Total Attachments: 2</b>	
source=Executed Takeda Pharmaceuticals Inc. to Resolve Asssignment RSN-018US_4838-3168-6020_2#page1.tif	
source=Executed Takeda Pharmaceuticals Inc. to Resolve Asssignment RSN-018US_4838-3168-6020_2#page2.tif	

## ASSIGNMENT

WHEREAS, I/WE

**Takeda Pharmaceutical Company Limited**

hereinafter referred to as Assignor(s), have invented a certain invention entitled:

### **OPTIMIZED BINUCLEASE FUSIONS AND METHODS**

for which invention an application (provisional or non-provisional) for a U.S. patent was filed on July 1, 2016, under U.S. Application No. 62/357,756, and

WHEREAS, **Resolve Therapeutics, LLC** of 454 North 34<sup>th</sup> Street, Seattle, Washington 98103, a Delaware corporation, hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in, to, and under the invention described in the patent application, including the entire priority right derived from the application,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor(s) assign and transfer to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, and other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, and utility model applications) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, and the patents that may issue thereon,

Assignor(s) convey to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor(s) will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor(s) will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention,

and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor(s) and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor(s) authorize Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor(s) and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment, as evidenced by the signature of an officer or authorized representative of Assignee below.

IN WITNESS WHEREOF, Assignor has hereunder set his/her hand on the date shown below.

Date November 9, 2016

  
\_\_\_\_\_  
Yoichi Okumura, Global Head of IP